Emerging and Evolving Biomarkers: MGMT
Tejus A. Bale, MD, PhD
Lauren Ritterhouse, MD, PhD
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
The O6-methylguanine-DNA methyl-transferase (MGMT) gene encodes a widely expressed DNA repair enzyme, which reverses the anti-tumor effects of alkylating agents. Silencing of the MGMT gene, via promoter methylation, has emerged as a biomarker of interest in glioma with regards to tumor prognostication and treatment selection. In the era of numerous biologically relevant glioma biomarkers, the relative significance of MGMT testing will be considered, as well as the technical considerations and constraints surrounding commonly utilized assays.
- Describe the function of O6-methylguanine-DNA methyl-transferase (MGMT) and the effects of gene promoter methylation.
- Describe the clinical significance of MGMT promoter methylation with regards to glioma therapy and risk stratification.
- Discuss the commonly used technical approaches and platforms for molecular diagnostic testing for MGMT gene methylation.
- Outline the strengths and limitations of described testing approaches.
This webinar is part 1 of the Emerging and Evolving Biomarkers Series.
Recording Date: June 30, 2020
Duration: 1 hr
Level of Instruction: Basic
CME/CMLE credit: 1.00 hour
SAM credit: 1.00 hour
Last Day to Claim CE Credit: December 31, 2022
How to claim credit:
To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey.
This course is approved by the American Board of Pathology for 1.0 SAM credits.Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).* You may not submit SAMs and CME/CMLE credit for the same content.
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.